Home
Search results “Activus pharma generic drug”
Actavis - think smart medicine
 
00:31
Actavis Group is one of the world's leading players in first-class generic pharmaceuticals and the new name in hospital pharmaceuticals.
Views: 1779 ActavisTV
Actavis - Twice As
 
02:08
This brand film was produced for the day one launch of the merged Watson Pharmaceutical + Actavis global enterprise creating the 3rd largest generic drug company in the world. The Tribe production was soup-to-nuts: discovery-strategy, scripting, shooting all original footage in three US facilities, one in Europe and one in India, and complete post-production here in Chatham (editing, music, voice-over casting, recording narrator, etc). We simultaneously produced an internal employee video for 17,000 employees worldwide to help reinforce the new culture.
Views: 1227 Tribe Pictures
Actavis to Purchase Forest Labs in $25B Pharma Deal
 
03:57
Feb. 18 (Bloomberg) -- Bloomberg News' Cristina Alesci reports on the $25 billion deal for Forest labs by Actavis to increase its focus on branded medicine on Bloomberg Television's "Bloomberg Surveillance." -- Subscribe to Bloomberg on YouTube: http://www.youtube.com/Bloomberg Bloomberg Television offers extensive coverage and analysis of international business news and stories of global importance. It is available in more than 310 million households worldwide and reaches the most affluent and influential viewers in terms of household income, asset value and education levels. With production hubs in London, New York and Hong Kong, the network provides 24-hour continuous coverage of the people, companies and ideas that move the markets.
Views: 4807 Bloomberg
Perrigo Company CEO: A Generic Grower | Mad Money | CNBC
 
06:08
This generic drug giant stock has taken a beating so far this year. Is it prime to snap this one up or is there a healthier option? » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC » Watch more Mad Money here: http://bit.ly/WatchMadMoney "Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money. About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more. Get More Mad Money! Watch full episodes: http://bit.ly/MadMoneyEpisodes Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter Like Mad Money on Facebook: http://bit.ly/LikeMadMoney Follow Cramer on Twitter: http://bit.ly/FollowCramer Connect with CNBC News Online! Get the latest news: http://www.cnbc.com Find CNBC News on Facebook: http://cnb.cx/LikeCNBC Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC Follow CNBC News on Google+: http://cnb.cx/PlusCNBC Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC Perrigo Company CEO: A Generic Grower | Mad Money | CNBC
Views: 3396 CNBC
How to Buy Prescription Drugs in Mexico without a Prescription
 
08:23
As a full time RVer, medical insurance and prescription management can be challenging. Recently I ran out of my migraine medicine so took a trip to Mexico to buy my meds over the counter. This video shows how to buy prescription drugs in Mexico and answers questions about what can and can NOT be bought. Watch and join me as I visit Mexico with my friend Bob to stock up on prescription medicine.
Views: 105532 Carolyn's RV Life
PHARMA NEWS #173 | Aurobindo Annora Actavis Pharma Jobs For Freshers & Experience #PharmaGuide
 
11:02
PHARMA NEWS #173 | Aurobindo Annora Actavis Pharma Jobs For Freshers & Experience #PharmaGuide Hi am Radhakrishna, Here am providing pharma guidance and hospital guidance for freshers. How to get Pharma Job Govt sector or private sector, How to fulfil Interview phobia, How to behave with consultancies, How to get Abroad Jobs, How to write entrance exams like MOH, DHA, HAAD, PROMETRIC, How to fulfil job experience, Pharma Industries and their job opportunities, How to survive in Pharma Industry, What is the growth in Pharma Industry? What are the features of Hospital Jobs? Here am giving an introduction to Pharma category job and their importance. ******************************************************** Pharma Guide channel is the first Indian YouTube channel to share Pharmaceutical guidance and Hospital guidance in Telugu. ********************************************************  For subscribe: goo.gl/AKbA2Y  Facebook: goo.gl/csuyjx  FB page: goo.gl/1mfKMH  Gmail: radhakrishnakotapati1481@gmail.com  Twitter: goo.gl/DhvNes  Website: http://pharmaguideradhakrishna.com/  Blog: http://pharmaguideradhakrishna.blogspot.com/  Google+: goo.gl/C2FVHR **************************************************************** #PharmaGuide #PharmaGuideRadhakrishna
Views: 699 Pharma Guide
Actavis - 60 years in the pharmaceutical industry in Dupnitza
 
01:58
proTechnica EVENT: Light, sound, multimedia, truss Client: Re:quest Date: 01.08.2014 Place: Dupnitza
Views: 170 proTechnicaEVENT
Gabapentin/Neurontin Review
 
07:05
Gabapentin/Neurontin, is a medication used primarily for seizure disorders and pain associated with the nerves. It can be used for nerve pain related to the herpes virus or shingles. It is also commonly used by diabetics who have suffered nerve pain. I find that this medication continues to work wonder for me, even after daily use for 3+ years. It helps prevent my migraines (at least it seems to) and once I have one, it helps the dull the pain. It also has help with occasional back pain problems. It has been a life saver for my insomnia. I am able to cope better with my day to day task because this medication helps me cope with my Clinical Depression, of which has haunted me since the passing of my father. There is no such thing as a miracle pill or a miracle cure for anything, but this medication has been a huge help for me over the years. Thanks for reading/watching my video.
Views: 207934 Alicia Hayes
Watson Pharmaceuticals Celebrates Rebranding with Name and Symbol Change
 
00:57
Executives and guests of Watson Pharmaceuticals, Inc., will visit the New York Stock Exchange to celebrate its new global name — Actavis — and a multi-year rebranding, including a new ticker symbol. To mark the occasion, Paul Bisaro, President and CEO of Watson, and members of Watson's executive leadership team will ring the NYSE Closing Bell. About Watson Pharmaceuticals, Inc. (NYSE: WPI) Watson Pharmaceuticals, Inc. (NYSE: WPI) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland. Watson is the world's third-largest generics manufacturer, with more than 750 products marketed globally through operations in more than 60 countries. Watson's global branded pharmaceutical business develops and markets products principally in Urology and Women's Health, and is committed to developing and marketing biosimilars products in Women's Health, Oncology and other therapeutic categories. In addition, Watson is the fourth-largest U.S. generic pharmaceutical product distributor through its Anda, Inc. business, and also develops and out-licenses generic pharmaceutical products outside of the U.S. through its Medis third-party business. Watson has announced that it will adopt a new global name -- Actavis -- effective in 2013.
Views: 2021 NYSE
Teva to Buy Allergan Generic Drug Business for $40.5 Billion
 
01:05
Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a deal that will turn Teva into one of the top 10 pharmaceutical companies. The acquisition should help Israel-based Teva, already the world's largest generic drugmaker, boost growth at a time its top drug, multiple sclerosis treatment Coxaprone, is facing competition. Allergan's generic business is generally seen as a better fit than Teva's previous target Mylan because it will improve Teva's distribution channels and because Allergan is strong in so-called biosimilar drugs. Teva's shares jumped 10.6 percent in Tel Aviv after the deal was announced. Teva said in a statement it will pay $33.75 billion in cash and shares of Teva valued at $6.75 billion, representing a 10 percent stake in the Israel-based company. http://feeds.reuters.com/~r/reuters/topNews/~3/LD_PPr1Xq0M/story01.htm http://www.wochit.com This video was produced by Wochit using http://wochit.com
Views: 726 Wochit Business
Pharmaceutical deals
 
02:40
A few big deals are being done -- Actavis buying Warner Chilcott, and Valeant purchasing Bausch & Lomb - but is this the start of another bout of industry consolidation or just more defensive moves? Lex's Julia Grindell and Vincent Boland discuss. For more video content from the Financial Times, visit http://www.FT.com/video
Views: 363 Financial Times
Analytical Services for Generic Pharmaceuticals Part 1
 
02:13
Gateway Analytical offers analytical testing and consulting services for generic pharmaceutical company's that provide a unique advantage. Learn about the advantages of working with Gateway Analytical from Oksana Olkhovyk, Ph.D. Senior Scientist.
Views: 174 GatewayAnalytical
FTC v. Actavis Inc.: Oral Argument - March 25, 2013
 
01:01:19
Facts: In 2000, Solvay Pharmaceuticals successfully patented AndroGel, a topical gel medication. Shortly after the FDA approved the medication, generic drug manufacturers Watson Pharmaceuticals and Paddock Laboratories began developing generic versions of the gel. Solvay filed a patent infringement suit against Watson and Paddock, but the manufacturers counter-claimed that Solvay's patent was invalid to begin with. As the infringement suit progressed, Solvay feared that it would lose its monopoly on AndroGel. To prevent this, Solvay entered into a reverse payment agreement with the two manufacturers. In return for dropping the suit and maintaining exclusivity, Solvay agreed to pay the manufacturers a sizeable fee. The agreement allowed Solvay to maintain its monopoly, despite the possible invalidity of the patent, in exchange for sharing some of the profits with its potential competitors. Shortly after entering the agreement, the Federal Trade Commission ("FTC") filed a complaint against the pharmaceutical companies. The FTC claimed that Solvay was unlikely to win the patent infringement suit; therefore the settlement unfairly protected an invalid patent monopoly. By limiting competition in the AndroGel market, the manufacturers were restraining trade in violation of antitrust laws. The manufacturers argued that the FTC failed to state a valid claim because the agreement merely protected Solvay's already existing patent rights. The United States District Court for the Northern District of Georgia agreed with the manufacturers and dismissed the case. The FTC appealed to the United States Court of Appeals for the Eleventh Circuit, which affirmed the lower court's decision. The appellate court explained that the manufacturers' reverse payment settlement is lawful as long as it restrains competition in the same way that patent protection typically restrains competition. Question: Are reverse payment agreements per se lawful, rather than presumptively anticompetitive? Conclusion: No. Justice Stephen G. Breyer delivered the opinion for the 5-3 majority. The Court held that reverse payment settlements are not presumptively unlawful and that the FTC's lawsuit should have been allowed to proceed. Although patent-based settlement agreements can sometimes violate anti-trust laws, the Court declined to apply an all-or-nothing rule regarding these agreements. Instead, the Court stated that there are five considerations that should have allowed the consideration of FTC's case. These considerations are: 1) that specific restraints in the settlement agreement had the potential to adversely effect competition; 2) that certain anti-trust consequences will sometimes prove unjustified; 3) that if a reverse payment settlement can cause anticompetitive harm, the patent-holder likely has the power to bring about that harm as well; 4) an anti-trust claim may be more administratively feasible than the lower court believed; and 5) the fact that a large, unjustified reverse payment settlement risks anti-trust liability does not prevent litigating parties from settling their lawsuits. The Court held that these considerations outweighed the lower court's decision to provide anti-trust immunity to reverse payment settlements. Chief Justice John Roberts wrote a dissent in which he argued that the majority's decision discourages generic pharmaceutical companies from challenging patents because it eliminates the possibility of meaningful settlements. He argued that this decision instead forces generic companies into costly litigation that could be more efficiently handled through settlement negotiations. Justice Antonin Scalia and Justice Clarence Thomas joined in the dissent. For more information about this case see: https://www.oyez.org/cases/2012/12-416 Section 1: 00:00:05 Section 2: 00:25:30 Section 3: 00:56:00 PuppyJusticeAutomated videos are created by a program written by Adam Schwalm. This program is available on github here: https://github.com/ALSchwalm/PuppyJusticeAutomated The audio and transcript used in this video is provided by the Chicago-Kent College of Law under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License. See this link for details: https://creativecommons.org/licenses/by-nc/4.0/
Two generic drug makers with good medicine for the bulls.  Mylan (MYL) and Supernus Pharmaceutica..
 
04:27
Two generic drug makers with good medicine for the bulls. Mylan (MYL) and Supernus Pharmaceuticals (SUPN) Stock Market Mentor http://www.stockmarketmentor.com/?utm_source=youtube&utm_medium=ytchannel&utm_campaign=youtube
Views: 2661 Stock Market Mentor
Actavis Takes 'Codeine Syrup' Off Market Due to Rappers Turning Feigns!
 
06:27
DJ Akademiks speaks on the company 'Actavis' taking off 'Codeine Syrup' off the market due to its abuse by Rappers and urban youth who have glamorized and abused its use. Join our community on FB http://www.facebook.com/iamakademiks
Views: 106814 DJ Akademiks
Best India's Medicine Online Store - Retail Pharma
 
00:56
Best Medicine Online store offer to buy Online medicine, prescription drugs order medicine For free home Delivery our product. We provide you generic medicine at affordable rate.
Views: 1617 Retail Pharma
Pharmaceutical News: Actavis to achieve record revenues in 2012
 
04:13
Actavis positioned to achieve record revenues in 2012 and grow faster than the European generics industry For the first time ever in the history of Actavis, the Company aims to achieve record revenues of EUR 2bn this year, an all-time high. "We targeted this figure in our 2012 budget and are confident of achieving our goal. With revenues of EUR 1.6bn after nine months, we are right on track," asserts CEO Claudio Albrecht, taking stock of Actavis' positive performance during the first three quarters of the year. Employing the concept of "Think Smart Medicine", the Austrian manager (53) has successfully repositioned Actavis to face the challenges of the generics industry head on. "We took over the helm at Actavis in a very difficult situation and managed to turn the Company around much quicker than expected. Now we are proud to hand over a healthy and fast-growing company with extraordinary, well trained and talented people."
Views: 1715 Wirtschaftsvideo
News Update: Watson Pharma Climbing After Hours on Generic Hypertension Drug Approval
 
01:06
Shares of Watson Pharmaceuticals (NYSE:WPI) are trading 1.3% higher to $40.82 after hours Monday after the company announced that its subsidiary, Watson Laboratories, Inc. - Florida, has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydrochloride Extended-Release tablets, the generic equivalent to Biovail Laboratories International SRL's Cardizem® LA product. Watson intends to launch its generic version of Cardizem® LA immediately. Diltiazem Hydrochloride Extended-Release tablets are indicated for the treatment of hypertension. In 2009, Cardizem® LA had total U.S. sales of approximately $94.1 million, according to IMS Health.
Views: 905 TradeTheTrend
The Real Deal: Generic Drug Companies Not Li
 
02:44
GLENVILLE -86% of Americans now take generic drugs and while those medications may be cheaper than the name brands, you're unknowingly giving up the ability to sue if you run into any unforeseen complications with the medication. Generic drug makers have to stick close to the name-brand formula and labeling and the Supreme Court has ruled because of those rules, they can't be held liable if something goes wrong. Debbie from Glenville has lasting effects from a drug reaction she suffered following a knee replacement, "I figured I'd come home and everything would be fine," she says but that's not what happened. She and her doctors say a generic pain medication she was taking caused renal failure and by the time she got back to the hospital, she was in serious condition. "At that point, I had 1,177 liters of urine throughout my body‚it was awful, I was so bloated I couldn't bend down to pick anything up, my legs ached, my ankles hurt, I couldn't do the therapy for my knee replacement," she says. After months of recovering, Debbie brought her case to a lawyer, "they said that you can't sue because it's a generic drug‚it took six months of my life away and they just say, "no, you can't do it, you can't sue," she says. Under federal law, generic drug makers are not allowed to change the safety warnings on their labels in response to new risks and side effects until after the name brand maker has done so. And then, the change needs to be approved by the FDA which creates a big window of time when patients may be taking the generic without updated health information. The FDA recently delayed a new rule that would require generic drug makers to independently update warnings after getting major pushback from the industry. The Generic Pharmaceutical Association argues the new rule would increase the prices of generic drugs and open up the generic drug makers to more liability. Debbie says she wouldn't mind paying a little extra for a little more piece of mind, "It was a nightmare and I don't want other people going through it," she says.
Views: 126 CBS6 Albany
Actavis/Allergan Integration -- Presentation by Ulon Palm, PhD, Sr VP, Actavis
 
17:29
Dr. Ulo Palm, Senior Vice President and Head Global Brands Drug Development Operations at Actavis (now Allergan) provided an update during the SoCalBio Networking Forum on the status on the Actavis/Allergan integration. The acquisition of Allergan by Actavis valued at approximately $70.5 billion is the largest M&A deal in Southern California's Bioscience industry. Actavis is now the second largest biopharma employer in the Greater Los Angeles region (following Amgen) with R&D and manufacturing facilities in Irvine, Corona, Riverside, Carpinteria and Santa Barbara.
Views: 385 SoCalBio
Analyst Says Actavis' $25 Billion Purchase of Forest Labs is Smart
 
01:49
Drugmaker Actavis said on Tuesday that it will buy Forest Laboratories for approximately $25 billion. The deal stands to give Actavis a broader portfolio of pharmaceuticals, which would enable the combined company to sell more products to doctors and hospitals, according to James Molloy, Managing Director at Janney Montgomery Scott. Molloy explains why he believes the deal is a smart one for Actavis and weighs in on speculation over whether or not Forest Labs is likely to receive a better offer. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
In Business- Aurobindo To Buyout Actavis' EU Ops
 
00:44
Aurobindo Pharma has inked a deal to buy Actavis' generic operations in seven Western European countries. Aurobindo will pay $41 million for the Dublin-based drug maker's generic products, marketing authorizations and license rights in countries including France and Italy. Bloomberg TV India's Agam Vakil shares a detailed report. www.btvin.com
Views: 111 Bloomberg TV India
Actavis CEO on Allergan | Mad Money | CNBC
 
07:02
One of the best performing stocks in the market this year is at the center of an authentic Wall Street takeover war. Could it give your portfolio the lift it needs? » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC » Watch more Mad Money here: http://bit.ly/WatchMadMoney "Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money. About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more. Get More Mad Money! Watch full episodes: http://bit.ly/MadMoneyEpisodes Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter Like Mad Money on Facebook: http://bit.ly/LikeMadMoney Follow Cramer on Twitter: http://bit.ly/FollowCramer Connect with CNBC News Online! Get the latest news: http://www.cnbc.com Find CNBC News on Facebook: http://cnb.cx/LikeCNBC Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC Follow CNBC News on Google+: http://cnb.cx/PlusCNBC Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC Actavis CEO on Allergan | Mad Money | CNBC
Views: 11404 CNBC
Pharmacy Business Awards 2015  winner of the Innovation in Generics Award
 
00:57
Pharmacy Business Awards 2015 Winners of the Innovation in Generics Award Jonathon Wilson, Managing Director, Actavis
Views: 20 AMG MEDIA
Viagra vs Sildenafil
 
01:30
Dr Kieran Seyan discusses the differences between two popular drugs used to treat Erectile Dysfunction: Viagra and generic sildenafil.
What is a Generic Drug?
 
02:49
http://generic-drug-pharmacy.com Understanding generic drugs with clear explanation by a doctor. Using genenics with the same quality and effect as brand name but save your money. Ask your doctor in order try generic medication whenever possible.
Views: 638 genericdrugsonline
Aurobindo rallies nearly 7% on Actavis acquisition plans
 
00:59
Wwatch: "Kanhaiya Kumar's Full Speech at JNU Campus" → https://www.youtube.com/watch?v=_df-48pHzCA -~-~~-~~~-~~-~- Aurobindo Pharma rallied as much as 6.8 per cent in trade after the generics drug maker signed a binding offer agreement to acquire commercial operations of Dublin-based Actavis in seven Western European countries.
Views: 102 ET NOW
Kid Tef The difference between real and fake lean
 
02:23
https://www.youtube.com/watch?v=nPvaGeWj8Nw
Views: 857571 KiD Tef
Dexcel Pharma August 2013
 
01:45
Dexcel® Pharma is a leading international pharmaceutical company involved in all stages of the pharmaceutical process: from discovery and R&D, to the manufacture and marketing of more than 55 branded and generic products in over 140 dosages.
Views: 978 Angelika Sawatzki
Using Generic Drugs
 
02:49
Do you use generic drugs? Are they safe? Can they save you money? Tim Colligan, Director of Pharmacy at Optima Health, shares his insights into the value of using generic drugs.
Views: 1045 Optima Health
Actavis Video Animasyon
 
01:35
Created by Amil Toprak
Views: 263 conradpasa
Teva (TEVA) Beats on Q2 Earnings, Misses Sales, Shares Dip - August 2, 2018
 
05:23
Teva (TEVA) Beats on Q2 Earnings, Misses Sales, Shares Dip - August 2, 2018 Israel-based Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) is a global pharmaceutical company with a strong presence in the generics as well as branded markets. The company’s branded products include Copaxone (multiple sclerosis), Azilect (Parkinson’s disease) and respiratory products like ProAir and Qvar. In early Aug 2016, Teva acquired Allergan’s generics business – Actavis Generics and in Oct 2016 it acquired the latter’s Anda Inc., the 4th largest distributor of generic pharmaceuticals in the U.S.... BREAKING NEWS TODAY, Trump-America Military Totally Prepared Against JAPAN, USA TODAY Please Subscribe us and get the latest JAPAN News Alert daily.. About US : WE are sharing News with we always respect the source should each video, written source of it. There is no copyright infringement intended for the video and/or material used in this video. If you have an issue with posting this, please contact us and we can sort it out. COPYRIGHT RELATED ISSUES ONLY PLEASE. Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for fair use for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personal use tips the balance in favor of fair use Videos can use content-based copyright law contains reasonable use Fair Use We Bring You All The Latest News & Politics. Also We Show all President Donald Trump Press Conference, Speeches, Events. Including White House Press Briefing From The White House. All Of This You Can Watch At Our LIVE STREAM Right Here! Watch Debates From The Senate Floor, Enjoy Our Chat! We Got Full Speeces In HD. Watch news on top stories on president trump and politics news and top stories us news and world news. Original URL: https://www.zacks.com/stock/news/315316/teva-teva-beats-on-q2-earnings-misses-sales-shares-dip Follow us on G+: https://plus.google.com/105932474463889737955
Views: 15 Charles Hicks
Supernus v Actavis
 
02:02
Views: 104 VISHAL GOEL
Israel-Based Teva Pharmaceutical Industries Smacks Down With Mylan With $40B Bid
 
01:13
As Israel's Teva Pharmaceutical Industries (TEVA) unveiled its $82 per share bid for Mylan (MYL) Tuesday, the hostile takeover attempt may be a harbinger of things to come. As consolidation increases in the generics pharmaceutical area, it may leave very few companies standing as potential targets. Mylan already has an outstanding $29 billion offer for Perrigo (PRGO). Other big consolidators in the sector besides Teva include Actavis (ACT), Forest Laboratories (FRX) and Abbott Laboratories (ABT), The Deal's Laura Cooper reports. But as the deal field narrows and bigger deals are announced, they are also likely to draw the attention of regulators. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Generic medicines and drugs
 
01:01
Generic drugs are drugs and medicines, which is equivalent to the branded products in dose, strength, route of administration, quality, performance and intended use. It can also term refers to any type of drug marketed under the chemical name without advertising, or the chemical composition of the drug instead of the brand under which the drug is selling the name. Although it can not be associated with a particular company, the drugs are often subject to government regulations in the countries in which they are dispensed with. It is labeled with the manufacturer's name and generic name does not have the name of the United States or the international common name for the drug approved. #Generic medicines and drugs
Views: 20 suman gupta
Webinar : Hot Topics in Generic Drug Entry and Regulation
 
46:19
Hot Topics in Generic Drug Entry and Regulation -- Examining Recent Trends in Citizens Petitions , "Pay for Delay " Settlements and Strategies for Navigating the Delicate Intersection of IP and Regulatory Law Presented by Chad A. Landmon Partner Axinn, Veltrop & Harkrider LLP Examining the causes and effects of the recent uptick in citizens petitions Understanding the ever-changing review requirements Obtaining approval in light of pending citizens petitions Strategies for obtaining court review of petition decisions Update on the current status of recent trends in "pay-for-delay" settlements and the fallout from FTC v. Actavis Chad Landmon is a partner at Axinn, Veltrop & Harkrider LLP, where he chairs the FDA Practice Group and co-chairs the IP Group. Mr. Landmon has extensive experience in food and drug law and patent litigation and counseling. His patent litigation practice is national in scope and concentrates on the life sciences industry. Mr. Landmon maintains a particular focus on Paragraph IV litigation. Mr. Landmon provides counseling and litigation services relating to patent, FDA and antitrust issues involving the development and marketing of new and generic drug products. He has litigated a wide variety of Paragraph IV cases in numerous jurisdictions, including cases involving blockbuster drugs. His FDA matters involve petitioning FDA and litigating issues relating to the Hatch-Waxman Act, including marketing exclusivities, patent listing, certification and notification requirements, bioequivalence, labeling and other issues relevant to the FDA drug approval process. Mr. Landmon's practice also includes matters involving the intersection of the antitrust and patent laws, such as issues arising from the settlement of patent and Hatch-Waxman exclusivity disputes. Mr. Landmon frequently speaks and writes about issues relating to the Hatch-Waxman Act and pharmaceutical patent litigation.hatch
Views: 1668 Matt Godson
Blood Pressure and Heart Failure Meds Recalled
 
02:29
For the latest news across Belize, visit: http://edition.channel5belize.com/ A common drug used to control hypertension and help prevent heart failure is being voluntarily recalled in more than twenty-two countries because the drug contains a chemical that poses a potential cancer risk. Locally, the Ministry of Health is alerting healthcare professionals and patients of a precautionary recall of several prescription drugs containing the active ingredient, valsartan. The versions of valsartan that are being removed from shelves are made by Denk Germany, Actavis UK and and Teva Pharmaceuticals Industries Ltd. Pharmacies are also being asked to stop supplying the product and immediately return the stock to their supplier. News Five spoke with Chrystal Samouge of the Pharmacy Unit at the Ministry of Health about the product recall.
Views: 151 Channel 5 Belize
OMFG - Hello
 
03:46
'Feeling Sheepish'...http://bit.ly/SuicideSheepSpotify MERRY CHRISTMAS!!!! Download... https://bitly.com/alexomfghello OMFG https://soundcloud.com/alexomfg https://www.facebook.com/alexomfg https://twitter.com/AlexSavageOMFG http://www.alexomfg.com/ Sheepy on Spotify http://bit.ly/MrSuicideSheepSpotify Live Sheepy Stream! http://bit.ly/2kvdDdS Facebooobs https://www.facebook.com/MrSuicideSheep Follow on Soundcloud https://soundcloud.com/mrsuicidesheep Follow on Twitter https://twitter.com/mrsuicidesheep Website http://mrsuicidesheep.com Sheepy Shop http://bit.ly/2b8GvBm Submit Tracks http://bit.ly/2aPHMvw Hello produced by OMFG is licensed under Creative Commons. http://creativecommons.org/licenses/b...
Views: 195141681 MrSuicideSheep
Courts weigh in on generic drug delays
 
11:22
Are less-expensive generic drugs being delayed to market by so-called "pay for delay" deals between drug companies? That's the allegation of the Federal Trade Commission, which has made fighting the deals one of its top priorities. NewsHour Weekend correspondent Megan Thompson spoke to Ed Silverman who writes the Pharmalot Blog for the Wall Street Journal, and has covered the pharmaceutical industry for almost 20 years.
Views: 795 PBS NewsHour
Addiction
 
05:42
What causes addiction? Easy, right? Drugs cause addiction. But maybe it is not that simple. This video is adapted from Johann Hari's New York Times best-selling book 'Chasing The Scream: The First and Last Days of the War on Drugs.' For more information, and to take a quiz to see what you know about addiction, go to www.chasingthescream.com Support us on Patreon so we can make more stuff: https://www.patreon.com/Kurzgesagt?ty=h Get the music of the video here: https://soundcloud.com/epicmountain/addiction https://epicmountainmusic.bandcamp.com/track/addiction An interactive version of this video: http://www.addiction.mobydigg.de (works on mobile) Or follow us on social media or reddit: http://kurzgesagt.org https://www.reddit.com/r/kurzgesagt https://www.facebook.com/Kurzgesagt https://twitter.com/Kurz_Gesagt THANKS A LOT TO OUR LOVELY PATRONS FOR SUPPORTING US: T0T0S, Ryan OHoro, Matthieu de Canteloube, Vince, Thomas Shiels, Brian David Henderson, Jim Yang, Arnav Guleria, Clemens, Tahseen Mushtaque, Jochen, Vahur S, Harry, BurmansHealthShop, Nils Caspar, Holger Fassel, Jackson R Hanna, Pascal de Reuck, ByeongWook Lee, Guus Ketelings, Franko Papić, Thalia, Narat, Suchartsunthorn, Lorenz Zahn, Brian Aparicio, Jörg Vogelsang, Rashed Ali, Darwin Ranzone, Tyler Thornton, David Pfister, Han Saini, Ute Moll, Ioanna Bischinioti, Jenny Zhou, Vince Babbra. Avi Yashchin, Dan Cortes, Matt K, Phiroze Dalal, Marcelo Fernandes de Souza Filho, A La Mode, Tom Wardrop, Shawn Marincas, Pontus Attåsen, Paul, Marc Dumont, Robert McKone, Todd Binkley, Matthew von der Ahe, Thomas Russell, Erick, Vivek Kotecha, Artur Szczypta, Jeff Fellows, Daniel Duffee, Konstantin Shabashov, Tim drake, Mike Galles, Evgenia Yigitalieva, Vrm Vee Are Em, Timothy Noble Everything We Think We Know About Addiction Is Wrong Help us caption & translate this video! http://www.youtube.com/timedtext_cs_panel?c=UCsXVk37bltHxD1rDPwtNM8Q&tab=2
Company Profile: Watson Pharmaceuticals (WPI)
 
00:57
Watson Pharmaceuticals tries to have the best of both worlds, with operations in the US generics market and the higher-profit-margin branded drug business. The company's broad generics portfolio of about 140 products includes treatments for hypertension and pain, as well as smoking cessation products, antidepressants, and oral contraceptives. Its line of about 25 branded drugs focuses on urology and nephrology; it markets its branded products, including treatments for iron deficiency anemia and overactive bladder, to specialist physicians in the US. Additionally, Watson distributes its own and third-party products to independent pharmacies and health care providers through its Anda and Valmed subsidiaries
Views: 735 TradeTheTrend
Highlights of GPhA 2013: CEOs Unplugged
 
01:25:00
Discussion featuring Donald DeGolyer, President, Sandoz, Inc.; Tony Mauro, President, Mylan North America; Thomas Moore, President, Hospira, Inc.; Allan Oberman, President & CEO, Teva Americas Generics and Siggi Olafsson, President, Actavis Pharma. Discussion moderated by Ronny Gal, Ph.D., Senior Analyst, Sanford C. Bernstein & Co. and Randall Stanicky, Managing Director, Equity Research, Specialty Pharmaceuticals, CANACCORD|Genuity
Views: 538 GPhAonline
'Pay for Delay' Ruling (6/17/13)
 
02:05
The U.S. Supreme Court ruled Monday that the government can challenge the so-called "pay for delay" deals—deals that pharmaceutical companies make with generic drug companies to delay releasing their less expensive, generic drugs. Hampton Pearson has the story for NBR.
Views: 211 NBRbizrpt
Ministry of Health On Top of Meds Recall
 
01:25
For the latest news across Belize, visit: http://edition.channel5belize.com/ Earlier this week, we reported on a common drug that is being voluntarily recalled because the drug contains a chemical that may expose patients to cancer risk. The drug valsartan is used to control hypertension and to help prevent heart failure, but it’s a contaminant that was included in the manufacturing process that’s poses the cancer risk. The Ministry of Health has called for the precautionary recall – and brands such as Denk Germany, Actavis UK and Teva Pharmaceuticals are being removed by importers and wholesalers. When we caught up with the Director of Health Services Doctor Marvin Manzanero he says that there is no need for patients to fear.
Views: 129 Channel 5 Belize
Given Compelling Valuation, Jim Cramer Is Bullish on Actavis
 
02:02
Actavis' leadership has focused on launching generic drugs for patients with rare conditions – the pharmaceutical version of a niche market. Jim Cramer and Action Alerts PLUS Research Director Jack Mohr discuss why Actavis is severely undervalued and an extremely compelling healthcare investment at these levels. The company is not only a serial acquirer; it purchases great companies and makes them even better, through disciplined cost management, synergy realization and pipeline expansion. Its recent acquisition of Allergan is a true game changer, as it offers Actavis high-profile brands including Botox, Restasis and Namanda. The most exciting of these is Botox, which currently contributes $2 billion in annual sales. Subscribe to TheStreetTV on YouTube: http://t.st/TheStreetTV For more content from TheStreet visit: http://thestreet.com Check out all our videos: http://youtube.com/user/TheStreetTV Follow TheStreet on Twitter: http://twitter.com/thestreet Like TheStreet on Facebook: http://facebook.com/TheStreet Follow TheStreet on LinkedIn: http://linkedin.com/company/theStreet Follow TheStreet on Google+: http://plus.google.com/+TheStreet
Africa Drug Patents
 
03:53
The South African government is close to passing new laws about intellectual property including drug patents. Health activists say that could allow people to buy cheaper, generic medicines. But as Emilie Iob reports, a fight may be brewing over the move.
Views: 169 TV2Africa
Round Table -2: Pharma Shippers Forum
 
01:16:29
http://stattimes.com - Enno Osinga, SVP, Cargo, Amsterdam Airport Schiphol & Vice Chairman, TIACA moderates a round table discussion on the challenges and special needs of the pharma sector that depends on air cargo to move goods across the world. The forum saw participation of representatives of leading pharmaceutical companies in India. Venugopal G Somani, Joint Drugs Controller (India); Ryan Viegas, VP, Supply Chain & Procurement, Watson Pharma (Actavis); Raghuveer Gopalakrishna Kini, Executive Director, Pharmaceuticals Export Promotion Council of India (PHARMEXCIL); Nanne Onland, MD, Cargonaut; Deepak Kotak, Head, Life Science & Healthcare/Chemical, DHL Logistics and Radharamanan Panicker, CEO, Cargo Service Center share their thoughts and ideas during the session.
Views: 634 STAT Media
What Is The Generic Name For Concerta
 
00:46
If a provider prescribes concerta and authorizes generic substitution, what may i substitute nov 17, 2014 the food drug administration's announcement last week that two formulations might not work as well brand name oct 18, 2016 us (fda) center for (adhd) (methylphenidate hydrochloride) years after those who use recreationally without prescription take more than their prescribed dosage are at risk developing. The generic versions of this drug are available in four strengths. Jan 2, 2015 within the past few years, fda has given okay for generic manufacturers to market versions of brand name concerta (methylphenidate er). It affects chemicals in the brain and nerves that contribute to hyperactivity impulse control. 14, 2014 (healthday news) two generic versions of the attention deficit hyperactivity disorder drug concerta may not work as effectively as the concerta is a prescription product approved for the treatment of attention deficit hyperactivity disorder (adhd) as part of a total treatment program that may sep 1, 2013 bottom line if your generic concerta is imprinted with alza, you have the brand medicationalso, if you have one on hand, look for the you can now buy generic concerta. Concerta extended release tablets are used to treat attention deficit disorder (add), hyperactivity (adhd), and narcolepsy generic drug availability, manufacturer information, patent status on concerta jul 29, 2016 adderall the brand names of medications. Adderall a side by comparison healthline. Nov 7, 2016 based on an analysis of data, fda has concerns about whether or not two approved generic versions concerta tablets (methylphenidate hydrochloride extended release tablets), used to treat attention deficit hyperactivity disorder in adults and children, are therapeutically equivalent the brand name drug methylphenidate tablets; Brand should be given cautiously patients with a history sep 5, 2017 (methylphenidate) is central nervous system stimulant. Certain generics are no longer equivalent to brand name concerta. Concerta uses, dosage & side effects drugs. Concerta uses, dosage & side effects drugs certain generics are no longer equivalent to brand name concerta goodrx url? Q webcache. There are three manufacturers currently making generic concerta actavis (formerly watson), kremers (kudco), and mallinckrodt apr 15, 2014 however, you may or not know that brand name has a what strengths do methylphendiate er come in? . Adderall is a concerta (methylphenidate) drug information & product resources from mpr including dosage information, educational generic name and formulations on the methylphenidate (ritalin, ritalin sr, la, concerta, methylin, methylin er, daytrana, quillivant xr metadate cd, er) friday, nov. Generic versions of adhd drug not as effective fda webmd. Interestingly, the manufacturer of one generic methylphenidate, sold under various trade names, ritalin being most commonly brand names for methylphenidate include ritalin, concerta, aptensio, biphe
Views: 45 Green Help